Elanix Biotechnologies AG announces non-binding letter of intent with Oxford MEStar Ltd. in regard to setting up a JV to market GynRepair in China
Potsdam, November 22, 2016 – Elanix Biotechnologies AG today announced that the company has entered into a non-binding letter of intent (LOI) with Oxford MEStar Ltd (“MEStar”), an Oxford University spin-out. The LOI contains broad terms of a potential transaction whereby the two companies, together with Tianjin-based UniNova, might establish a Chinese JV. In the first instance this would market Elanix’s GynRepair, used for the treatment of vulvodynia, in the domestic market in China (PRC). The transaction is necessarily subject to entering into a definitive agreement between the parties, containing specific signing and closing terms and conditions yet to be finalised, negotiated and agreed up.
Professor Zhanfeng Cui, the founder of MEStar, commented: “We look forward to collaborating with Elanix, whose tissue repair products we believe have significant commercial potential”.
Tomas Svoboda, CEO of Elanix Biotechnologies AG, added: “We are very pleased to find such reputable partners that will accelerate our territorial expansion for our innovative bioactive creams”.
Tomas Svoboda, CEO
Oxford MEStar Limited is a spin-out company from the Institute of Biomedical Engineering of Oxford University specializing in translational and regenerative medicine and healthcare. The company is focused on a) developing novel technologies; b) offering bioengineering solutions to clients; and c) technology transfer between Europe and China.
For more information, please contact Dr Zoe Li on 01865 784436 or visit www.oxford-mestar.com
UniNova is the Oxford MEStar sister company, incorporated in Nov 2014 with 80 million RMB private investment and with the support of Tianjin Municipal Government. UniNova’s goal is to provide a one-stop solution for SMEs in biotechnology, biomedical and healthcare, so they can land in China smoothly and access the Chinese market in a timely manner.
Elanix Biotechnologies AG (Frankfurt SX: ELN) develops and commercializes tissue regeneration products for acute wound care, dermatological and gynaecological applications, and provides services in cell technologies. The company was founded in 2013 as a spin-out from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Elanix owns GMP certified Master and Working cell banks with vast quantities of cells of different cell types.
The Company is headquartered in Nyon, Switzerland with offices in Potsdam and listed on the Frankfurt stock exchange under the symbol ELN. For more information and updates, visit www.elanix-biotechnologies.com.
Phone number: +49 331 583 945 10
Disclaimer / Forward-looking statements:
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Elanix Biotechnologies AG. This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in the United States of America (the “United States”), Australia, Canada or Japan or in any jurisdiction to whom or in which such offer or solicitation is unlawful. The securities referred to in this announcement will not be and have not been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”) and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements under the U.S. Securities Act. Subject to certain exceptions, the securities referred to in this announcement may not be offered or sold in Australia, Canada or Japan, or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan. The offer and sale of the securities referred to in this announcement has not been and will not be registered under the U.S. Securities Act or under the applicable securities laws of Australia, Canada or Japan. There will be no public offer of the securities in the United States.
This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.